NCT05453396 2025-10-16
Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies
University of Washington
Phase 2 Recruiting
Clinical Trials
6 trialsNCT05672251 2025-10-06
Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
City of Hope Medical Center
Phase 2 Recruiting
NCT07197307 2025-09-29
CLEAR
Universität Münster
Phase 2 Not yet recruiting
NCT06977711 2025-08-05
Loncastuximab and Roflumilast Added to R-CHOP (Lo-(Rituximab and Roflumilast) RR-CHOP) for Naïve High-Risk Diffuse Large B-cell Lymphoma (DLBCL)
The University of Texas Health Science Center at San Antonio
Phase 1 Recruiting
NCT06918912 2025-04-09
LORELY
Istituto Clinico Humanitas
Phase 2 Recruiting
NCT05228249 2023-01-13
Loncastuximab Tesirine in Combination With Chemotherapy Prior to Stem Cell Transplant for the Treatment of Recurrent or Refractory Diffuse Large B-Cell Lymphoma
Fred Hutchinson Cancer Center
Phase 1 Withdrawn